To elucidate the effect of Ruanjian Qingmai granules on arteriosclerosis obliterans from the perspective of cholesterol efflux
Open Access
- 4 August 2025
- journal article
- medicine
- Published by Frontiers Media SA in Frontiers in Medicine
- Vol. 12, 1510927
Abstract
Aim of the study: To investigate the effect of Ruanjian Qingmai granules (RJQM) on arteriosclerotic obliterans (ASO) and identify its potential bioactive components.Materials and methods: Separate zebrafish atherosclerosis models and cellular lipid metabolism disorder models were established, and RJQM was administered at different concentrations for intervention. The lipid deposition was examined by using Nile Red staining. The expression levels of cholesterol metabolism-related genes were determined by using quantitative real-time PCR (qRT-PCR). The CYP7A1 inhibitor was utilized to elucidate the target of RJQM. Through network pharmacology and serum pharmacochemistry approaches, potential bioactive components were systematically identified and subsequently validated through experimental assays.Results: Ruanjian Qingmai granules significantly decreased lipid deposition and significantly increased the expression of CYP7A1 mRNA in both zebrafish and HepaRG cells. And this effect was attenuated by CYP7A1 inhibitors. Serum pharmacochemistry and network pharmacological analysis indicated that kaempferol and isorhamnetin were potential bioactive components in RJQM for the treatment of ASO. Both components could significantly reduce lipid deposition in zebrafish and HepaRG cells, and this effect was also diminished by CYP7A1 inhibitors. Molecular docking also confirmed that CYP7A1 might be the target of kaempferol and isorhamnetin, and qRT-PCR results also verified that both components could significantly up-regulate the mRNA expression level of CYP7A1.Conclusion: Ruanjian Qingmai granules exerts a therapeutic effect on ASO by up-regulating the expression level of CYP7A1 mRNA, thereby reprogramming lipid metabolism. Kaempferol and isorhamnetin are likely the main active components of RJQM in lipid metabolic reprogramming.Keywords
This publication has 51 references indexed in Scilit:
- MicroRNA-125b Affects Vascular Smooth Muscle Cell Function by Targeting Serum Response FactorCellular Physiology and Biochemistry, 2018
- The Interplay of Lipids, Lipoproteins, and Immunity in AtherosclerosisCurrent Atherosclerosis Reports, 2018
- Modeling hypercholesterolemia and vascular lipid accumulation in LDL receptor mutant zebrafishJournal of Lipid Research, 2018
- Real-world data to assess changes in low-density lipoprotein cholesterol and predicted cardiovascular risk after ezetimibe discontinuation post reporting of the Ezetimibe and Simvastatin in Hypercholesterolemia Enhances Atherosclerosis Regression trialJournal of Clinical Lipidology, 2017
- 2016 AHA/ACC Guideline on the Management of Patients With Lower Extremity Peripheral Artery Disease: A Report of the American College of Cardiology/American Heart Association Task Force on Clinical Practice GuidelinesCirculation, 2017
- The myth of restenosis after carotid angioplasty and stentingJournal of NeuroInterventional Surgery, 2015
- Kaempferol alleviates insulin resistance via hepatic IKK/NF-κB signal in type 2 diabetic ratsInternational Immunopharmacology, 2015
- Complication Rates and Center Enrollment Volume in the Carotid Revascularization Endarterectomy Versus Stenting TrialStroke, 2014
- Cholesterol and oxysterol metabolism and subcellular distribution in macrophage foam cells: accumulation of oxidized esters in lysosomesJournal of Lipid Research, 2000
- The Role of Lipids and Lipoproteins in AtherosclerosisScience, 1950